Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

Haematologica

Volumn 94, Issue 9, 2009, Pages 1266-1273

  Aue, Georg ^a   Njuguna, Ndegwa ^a   Tian, Xin ^a   Soto, Susan ^a   Hughes, Thomas ^b   Vire, Berengere ^a   Keyvanfar, Keyvan ^a   Gibellini, Federica ^a   Valdez, Janet ^a   Boss, Carol ^a   Samsel, Leigh ^a   McCoy Jr , J Philip ^a   Wilson, Wyndham H ^b   Pittaluga, Stefania ^c   Wiestner, Adrian ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD80; Chronic lymphocytic leukemia; Cytokine release syndrome; Lenalidomide; Tumor flare

Indexed keywords

ALLOPURINOL; B7 ANTIGEN; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; FAS ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BACKACHE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DEHYDRATION; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; IMMUNOPATHOLOGY; LEUKEMIA CELL; LEUKEMIA RELAPSE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PHASE 2 CLINICAL TRIAL; SHOCK; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; UPREGULATION;

AGED; ANTIGENS, CD80; ANTINEOPLASTIC AGENTS; CYTOKINES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SYNDROME; THALIDOMIDE; TIME FACTORS; UP-REGULATION;

EID: 70349150560     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.005835     Document Type: Article

References (19)

1. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-5349 (Pubitemid 46623164)
2. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-5297
3. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544-1552
4. Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-2525
5. Moutouh-de Parseval LA, Weiss L, DeLap RJ, Knight RD, Zeldis JB. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25:5047. (Pubitemid 350220451)
6. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952-4957
7. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-3464 (Pubitemid 44776887)
8. Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol 2006;7:480-488 (Pubitemid 43796153)
9. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999;163:380-386 (Pubitemid 29295864)
10. Davies FE, Raje N, Hideshima T, Lentsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216
11. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, et al. Immunomodulatory drug costimulates T cells via the B7- CD28 pathway. Blood 2004;103:1787-1790 (Pubitemid 38268973)
12. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-2437 (Pubitemid 351949771)
13. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001;69:81-88 (Pubitemid 32095121)
14. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Wiesdorf D, Andrey J, et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007;13:6168-6174 (Pubitemid 350075077)
15. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005;11:1490-1499 (Pubitemid 40315231)
16. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999;17:791-795 (Pubitemid 29109307)
17. O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:7697-7702 (Pubitemid 46291834)
18. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002; 277:7765-7775 (Pubitemid 34968223)
19. Hirokawa M, Kuroki J, Kitabayashi A, Miura AB. Transmembrane signaling through CD80 (B7-1) induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation. Immunol Lett 1996;50:95-98 (Pubitemid 26180006)